Description: Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and internationally. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures for use in medical testing kits, disease prediction, diagnosis, and treatment. Its products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic test for predicting response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.
Home Page: www.oxfordbiodynamics.com
3140 Rowan Place
Oxford,
OX4 2WB
United Kingdom
Phone:
44 1865 518 910
Officers
Name | Title |
---|---|
Dr. Jon Anthony Joseph Burrows B.Sc., M.Sc., Ph.D. | CEO & Executive Director |
Mr. Paul Leslie Stockdale F.C.A., M.A. | CFO & Executive Director |
Dr. Alexandre Akoulitchev M.A., Ma (Oxon), Ph.D. | Chief Scientific Officer & Executive Director |
Mr. Thomas G. Guiel B.A. | Chief Operating Officer |
David Blum | Senior Vice President of Marketing |
Dr. Steven Arrivo | Senior Vice President of Business & Corporate Development |
Dr. Ewan Hunter B.Sc., Ph.D., Ph.D., (KCL) | Chief Data Officer |
T. Demain | Company Secretary |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 1.529 |
Price-to-Sales TTM: | 17.0381 |
IPO Date: | |
Fiscal Year End: | September |
Full Time Employees: | 53 |